Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0B1CF
|
||||
Former ID |
DIB014913
|
||||
Drug Name |
PharmaPEG-EPO
|
||||
Synonyms |
Pegylated erythropoietin (hematological disease/immune disorder), Mountain View Pharmaceuticals; PharmaPEG-EPO (hematological disease/immune disorder); PharmaPEG-EPO (hematological disease/immune disorder), Mountain View Pharmaceuticals
|
||||
Indication | Hematological disease [ICD10:D50-D89] | Investigative | [543465] | ||
Company |
Mountain View Pharmaceuticals Inc
|
||||
Target and Pathway | |||||
Target(s) | Erythropoietin Receptor | Target Info | Modulator | [543465] | |
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
Pathway Interaction Database | Signaling events mediated by Stem cell factor receptor (c-Kit) | ||||
EPO signaling pathway | |||||
WikiPathways | EPO Receptor Signaling | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.